CFO Newton buys 200.0K shares of LYEL at $0.56 in cluster buy; stock at $9.67, -83.9% from 52-week high
Newton Charles W., CFO of Lyell Immunopharma, purchased 200,000 shares at $0.56, establishing an initial position worth $111.6K. This transaction coincides with a cluster pattern: 2 other insiders also bought within the past 14 days. The broader context is material: LYEL has declined -83.9% from its 52-week high of $60.20 and faces fundamental headwinds, including quarterly revenue of $34.0K, a net loss of $-44.6M in the most recent period, and annual revenue contraction of -53.1%. The stock is down -20.8% over the past 30 days and -18.7% over 90 days. Concurrent buying by multiple insiders during steep price declines and deteriorating financials warrants examination of whether this reflects informed conviction about company trajectory or liquidity/hedging motives unrelated to valuation.